Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilars Industry Urges Improved UK Evaluation Process

Follows ‘Milestone’ NICE Decision On Use Of Biosimilars For Moderate Arthritis

Executive Summary

A more efficient system to pave a path to market for biosimilars is needed in the UK, the British Biosimilars Association has urged, as it welcomed recent moves to broaden the use of adalimumab, etanercept and infliximab for treating moderate as well as severe rheumatoid arthritis.

You may also be interested in...



BGMA ‘Astonished’ By UK Government Snub

The UK government’s new Life Sciences Vision “entirely ignores” the off-patent industry, representing an “astonishing” snub given the value of the sector to the NHS and its critical role in fighting the COVID-19 pandemic, according to BGMA chief Mark Samuels.

NICE Decision On Arthritis Opens Door For Biosimilars

A decision by the UK’s NICE opens the door to broaden the use of adalimumab, etanercept and infliximab by using them to treat moderate as well as severe rheumatoid arthritis.

UK Pioneers Tailored Biosimilars Pathway With Fresh Guidance

Updated guidance on the UK’s new licensing pathway for biosimilars – which will typically not require comparative efficacy data – has been published by the MHRA after a stakeholder consultation, receiving a warm welcome from the off-patent industry both locally and internationally.

Topics

UsernamePublicRestriction

Register

GB151090

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel